As a leading CRO of antibody generation and development, Creative Biolabs offers application-specific antibody development services to global clients. With experienced scientists and advanced technology, we have established a series of high-quality in vitro diagnostic (IVD) antibody & immunoassay development services against biomarkers of different diseases, such as gelsolin (GELS) biomarker.
GELS was first found in rabbit pulmonary macrophage in 1979 and named for its capability to stimulate the transformation of gel-sol of cytoplasm which enriched with actin in a Ca2+ dependent manner. Gelsolin is one of the most powerful members of actin filament severing and/or capping gelsolin protein superfamily which has seven different proteins containing homologous repeats of the gelsolin-like domain, including CapG, adseverin, scinderin, flightless I and villin. Gelsolin is in both intracellular and extracellular fluids (such as plasma) and its molecular weight is about 80-83 kDa. It contains six domains (each domain has a Ca2+-binding site) named as S1-S6 from the N-terminus to C-terminus. As a powerful actin-regulating protein, gelsolin is expressed not only in normal cells but also in malignant transformation cells. Gelsolin participates in the formation of podosomes and inhibits apoptosis by stabilizing the mitochondria. Interestingly, gelsolin is considered as both tumor enhancer and tumor suppressor depending on different cell types.
Fig.1 The structure of gelsolin.
The extracellular isoform of GELS has been recognized as a potential biomarker of inflammatory-associated medical conditions. Many studies have reported that blood GELS levels are significantly decreased in humans in conditions requiring urgent medical attention, such as tissue injury, organ damage, acute oxidant lung injury, traumatic brain injury, radiation-induced injury, acute liver failure, myocardial infarction, septic shock, and so on. Besides, plasma GELS is a potential sepsis biomarker as indicated by many publications. For instance, researchers found a significant reduction in mean GELS concentrations when compared with healthy individuals in 51% of patients with sepsis, which correlated with illness severity. What’s more, GELS was found to be implicated in cancer development. Studies have reported serum GELS, together with lumican, can be used as a highly sensitive combined biomarker for distinguishing pancreatic cancer and pancreatitis. Also, the utility of GELS in body fluids other than plasma can be used in early cancer detection.
As a technology-based service provider of antibody (pair) generation, Creative Biolabs launches a unique platform for biomarker-specific antibody development, pairing, characterization, and engineering services to global clients. We know the importance of high-quality antibodies and antigens for achieving high sensitivity and accuracy of immunoassays. Also, we can offer support in different steps of the assay development process, including assay design, assay development, validation, and kit production. For more detailed information, please click the following links:
Please feel free to contact us for more information and discuss your project needs.
Reference
For Research Use Only.
